Post-finasteride syndrome
An. bras. dermatol
;
95(3): 271-277, May-June 2020. tab
Artículo
en Inglés
| LILACS, ColecionaSUS
| ID: biblio-1130879
ABSTRACT
Abstract Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Disfunciones Sexuales Fisiológicas
/
Finasterida
/
Inhibidores de 5-alfa-Reductasa
Tipo de estudio:
Estudio diagnóstico
/
Estudio de etiología
/
Factores de riesgo
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
An. bras. dermatol
Año:
2020
Tipo del documento:
Artículo
Institución/País de afiliación:
Universidade Federal de Minas Gerais/BR
Similares
MEDLINE
...
LILACS
LIS